Taken together, the past 3 years of approvals represent drug companies’ most productive period in more than 2 decades. Still, some analysts caution that the steady flow of new medicines could mask ...
A study released earlier this month offers data that will likely crystallize the unease felt by patients seeking a break from the sky-high price of drugs. Between 2007 and 2018, the net cost of all ...
Recent press reports and other evidence suggest that Medicare Part D plans may be encouraging the use of brand-name drugs instead of generics. However, the scope of such practices is unclear. We ...
The U.S. federal government spent an estimated $1.8 billion in Medicare funds in 2019 on drugs whose clinical benefits have yet to be confirmed by the Food and Drug Administration, a study led by ...
WASHINGTON — Lawmakers of all stripes made an agreement the day following the midterm elections last November: While they might not agree on much, they would work together to lower prescription drug ...
But it’s also a reality — one that many politicians and pundits on the left seem eager to ignore — that cutting drug prices will mean companies spend less money on research and development. The result ...
Uncertainties about the benefits and harms of new drugs are common at the time of drugs’ approval. It is unclear to what extent the Food and Drug Administration (FDA) communicates these uncertainties ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results